GH Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
335.0M
+11.0%
301.7M
+7.3%
281.3M
+6.1%
265.2M
+14.3%
232.1M
Cost of Revenue
115.9M
+10.5%
104.9M
+5.5%
99.5M
+6.3%
93.6M
+15.2%
81.2M
Gross Profit
219.0M
+11.3%
196.7M
+8.2%
181.8M
+5.9%
171.6M
+13.7%
150.9M
Operating Expenses
348.1M
+9.4%
318.1M
+5.1%
302.6M
+11.8%
270.6M
+5.2%
257.3M
R&D
96.5M
+6.0%
91.0M
-7.4%
98.3M
+9.2%
90.0M
+2.9%
87.4M
SG&A
251.6M
+10.8%
227.1M
+11.1%
204.3M
+13.1%
180.6M
+6.4%
169.8M
Operating Income
-129118000
-6.4%
-121350000
-0.5%
-120805000
-22.0%
-98989000
+7.0%
-106413000
EBITDA
-119557000
-6.8%
-111908000
-1.0%
-110755000
-23.6%
-89581000
+7.0%
-96371000
Net Income
-120142000
-7.2%
-112075000
+12.8%
-128494000
-38.6%
-92725000
+7.2%
-99899000
EPS (Basic)
$-0.90
-5.9%
$-0.85
+15.0%
$-1.00
-35.1%
$-0.74
+7.5%
$-0.80
EPS (Diluted)
$-0.90
-5.9%
$-0.85
+15.0%
$-1.00
-35.1%
$-0.74
+7.5%
$-0.80
Shares (Diluted)
132.9M
+1.2%
131.3M
+2.0%
128.7M
+3.1%
124.8M
+0.6%
124.1M
Guardant Health (GH) โ€” Financials